Barrett Katz

Barrett is an internationally recognized neuro-ophthalmologist with deep experience in clinical development of therapeutics to treat eye diseases. He came to Viridian Therapeutics in 2021 from BridgeBio Pharma, Inc. where he developed therapeutics to treat orphan eye diseases as President and CMO of Retinagenix Therapeutics and Fortify Therapeutics. Prior to BridgeBio, Barrett served as CMO at GenSight Biologics, S.A. in Paris, where he oversaw early- and late-stage clinical programs. He held the Francis DeJur Chair of Ophthalmology at the Montefiore Medical Center and Albert Einstein College of Medicine in New York, serving as Professor of Ophthalmology, Neurology and Neurosurgery as well as Executive Director of the Office of Clinical Trials. He previously served as CEO of Danube Pharmaceuticals, CMO of Fovea Pharmaceuticals and VP for Medical Affairs and Strategy at Eyetech. 

Barrett received an M.D. from Case-Western Reserve University School of Medicine, an M.B.A. from the University of Rochester’s Simon School of Business, and an A.B. from Colgate University.